Advisor Website Home | Contact Us | Site Map | Help | Career Opportunities

Detailed Fund Information

AMCAP Fund® (growth fund)

Class A shares

Select a fund and share class

How do the share classes differ?

Daily Prices

Updated April 17, 2014, 3:19PM Pacific time

Net Asset Value (NAV) $27.82
NAV Change $0.05
Maximum Offering Price (MOP) $29.52

(All prices are subject to revision.)

Historical Prices & Distributions

Choose a date

Ticker Symbols & Fund Numbers

Fund Number 02
Ticker/Quotron Symbol AMCPX
CUSIP Number 023375 10 8

Fund Description

Fund Objective The fund's investment objective is to provide long-term growth of capital.
Distinguishing Characteristics Seeks long-term growth of capital by investing primarily in U.S. companies that have solid long-term growth records and the potential for good future growth.
Types of Investments Primarily invests in U.S. common stocks, as well as convertible preferred stocks and cash and equivalents.
Non-U.S. Holdings This fund may invest in securities outside the U.S. to a limited extent.

Fund Facts

Minimum Initial Investment $250
Shareholder Accounts (aggregated for all share classes; updated monthly) 1,785,642
Regular Dividends Paid June, December
Capital Gains Paid June, December
Fund Inception May 1, 1967
Fiscal Year-End February

The months indicated for dividends and capital gains paid represent the anticipated current year ex-dividend date schedule for all share classes.

Returns & Expenses

Figures shown are past results and are not predictive of results in future periods. Current and future results may be lower or higher than those shown. Results shown at net asset value have all distributions reinvested. If a sales charge had been deducted, the results would have been lower. Share price and return will vary, so investors may lose money. Investing for short periods makes losses more likely. Investments are not FDIC-insured, nor are they deposits of or guaranteed by a bank or any other entity, so they may lose value. Returns with sales charge for Class A shares reflect payment of the 5.75% maximum sales charge at the beginning of the stated periods. Definitions and other important legal information about these prices and returns are shown below.

Rates of Return*

  Average Annual Total Returns
1 yr 3 yrs 5 yrs 10 yrs Fund Lifetime
March 31, 2014 (most recent month-end)
NAV 27.67% 15.82% 22.28% 8.02% 11.66%
With sales charge 20.33% 13.56% 20.84% 7.39% 11.51%
March 31, 2014 (most recent quarter-end)
NAV 27.67% 15.82% 22.28% 8.02% 11.66%
With sales charge 20.33% 13.56% 20.84% 7.39% 11.51%

Interactive Results Graphs

Expense Ratios

AMCAP Fund 0.74%
Lipper Growth Funds Average 1.31%

12-Month Distribution Rates

As of March 31, 2014 (updated monthly)

NAV 0.22%
With sales charge 0.21%

Annualized 30-Day SEC Yield

As of March 31, 2014 (updated monthly)

With sales charge 0.24%


Largest Industry Holdings

% of net assets as of March 31, 2014 (updated quarterly)

Biotechnology 10.1%
Software 5.9%
Semiconductors & semiconductor equipment 5.1%
Health care equipment & supplies 4.9%
Oil, gas & consumable fuels 4.3%
Health care providers & services 4.2%
Energy equipment & services 4.1%
Internet software & services 3.8%
Media 3.2%
IT services 2.7%

Portfolio Holdings

(updated quarterly, upon availability)

Asset Mix

as of March 31, 2014 (updated monthly)

U.S. Equities 82.4%
Non-U.S. Equities 5.7%
Cash & Equivalents 11.9%

Assets and Portfolio Turnover (for fiscal years)

Fiscal Year Fund Assets (billions) Portfolio Turnover
2014 $39.2 29%
2013 $27.5 27%
2012 $24.2 31%
2011 $23.2 28%
2010 $19.6 29%

Assets shown are for combined share classes.

Largest Equity Holdings

Percent of net assets as of March 31, 2014 (updated monthly)


Gilead Sciences

Develops drugs to treat infectious diseases and cancer.



One of the most frequently used website search engines in the world.



Major supplier of database management software. Also develops business applications and provides consulting and support.


Biogen Idec

A leader in developing therapies to treat multiple sclerosis and cancer.



The world's largest biotechnology company.



Internet subscription service for watching TV shows and movies.


Alexion Pharmaceuticals

Biopharmaceutical company focused on treating severe and ultra-rare disorders.



A leading provider of services and technology to the petroleum industry.



Digital television services provider in the United States, Latin America and the Caribbean.


Texas Instruments

Global designer and producer of semiconductors.


Portfolio Managers

Number of years with American Funds or affiliates
Barry S. Crosthwaite 17
Claudia P. Huntington 38
Eric S. Richter 14
C. Ross Sappenfield 21

(as of the prospectus dated May 1, 2013)

The portfolio managers shown are reflected in the fund’s most recent prospectus.

Important Legal Information

* Investment results assume all distributions are reinvested and reflect applicable fees and expenses.

  When applicable, investment results reflect fee waivers and/or expense reimbursements, without which results would have been lower. Read details about how waivers and/or reimbursements affect the results for each fund.

Source for Lipper expense ratio comparison: Lipper, based on front-end load funds, excluding funds of funds, for the most recent fiscal year-ends available as of March 31, 2014. The fund’s expense ratio is as of the fund’s prospectus. The expense ratios do not reflect sales charges.

The SEC yield reflects the rate at which the fund is earning income on its current portfolio of securities, while the distribution rate reflects the fund's past dividends paid to shareholders. Accordingly, the fund's SEC yield and distribution rate may differ.

Investors should carefully consider investment objectives, risks, charges and expenses. This and other important information is contained in the fund prospectuses, summary prospectuses and CollegeAmerica Program Description, which can be obtained from a financial professional and should be read carefully before investing. CollegeAmerica is distributed by American Funds Distributors® and sold through unaffiliated intermediaries.